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1. Why this case is important
We describe a rare case of hantavirus cardiopulmonary syn-
drome (HCPS) diagnosed in a United Kingdom resident who
returned from Panama in July 2014; this represents only the third
publishedcaseofHCPS imported inEurope todate. Serological anal-
ysis identiﬁed increasing titres of hantavirus IgG antibodies over
the courseof illness anddetectionofhantavirusRNA in serumtaken
seven days after onset of symptoms. Sequence analysis following a
pan-hantavirus diagnostic assay conﬁrmed the presence of Choclo
hantavirus, a species of hantavirus known to circulate in Panama
and suspected of causing several cases of severe human disease in
the Los Santos region of Panama during 2014. A set of molecular
assays was designed to characterize the S segment of the genome
and to provide rapid molecular identiﬁcation for future cases.
2. Case description
A 35-year-old British woman returned to the United Kingdom
(UK) on 16th July, 2014 following a nine month stay in the Los
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Santos province of Panama with her partner who worked locally
as a rice farmer. They lived in a rural area that they had visited
frequently over the last ten years. In the weeks prior to her return,
she had swept out a shed that had evidence of rodent infestation
and handled packaged horse feed which had evidence of rodent
damage.
On 13th July, while in Panama, she developed fever, myalgia,
lethargy, headache and rigors. After returning to UK, symptoms
progressed to include vomiting, cough, rapidly progressive dysp-
noea and chest tightness. She presented at her local Accident and
Emergency department on 18th July and was admitted to hospital.
On admission she was pyrexial, hypoxic (oxygen saturation
88%) and tachycardic (heart rate 110 beats per minute). Nei-
ther rash nor bleeding were evident. Chest examination revealed
bilateral crepitations. Haemoglobin levels were 191g/L (norm:
120–160g/L), haematocrit was 0.52 (norm: 0.36–0.46), platelet
count was 65×109/L (norm: 150–400×109/L), neutrophils were
12.76×109/L (norm: 2–8×109/L) and alanine transferase levels
were 160U/L (norm: 10–40U/L). Blood gas analysis showed arte-
rial oxygen partial pressure of 8.9 kPa (norm: 11–13kPa) with a
pH of 7.25 (norm: 7.34–7.44); all other indices were within normal
parameters.
A chest X-ray showed bilateral perihilar ground-glass opaciﬁca-
tionandnormal cardiac contours. Shewasadmitted to the intensive
http://dx.doi.org/10.1016/j.jcv.2015.04.007
1386-6532/Crown Copyright © 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
B. Atkinson et al. / Journal of Clinical Virology 67 (2015) 52–55 53
Table 1
Primer information for molecular assays used to diagnose clinical samples, produce complete S segment sequence data and monitor isolation attempts.
Primer pairs Sequence Positiona (strand) Product size Comment
HAN-L-F1
HAN-L-R1
ATGTAYGTBAGTGCWGATGC
AACCADTCWGTYCCRTCATC
L 2940 (sense)
L 3391 (antisense)
451 base pairs Pan-hanta assayb
1st round (nested)
HAN-L-F2
HAN-L-R2
TGCWGATGCHACIAARTGGTC
GCRTCRTCWGARTGRTGDGCAA
L 2951 (sense)
L 3340 (antisense)
389 base pairs Pan-hanta assayb
2nd round (nested)
CHOV S 1 F
CHOV S 719 R
TAGTAGTAGACTCCTTGAGAAGC
CCAAAACCGATGACACCC
S 1 (sense)
S 719 (antisense)
719 base pairs CHOV sequencing
Primers set 1
CHOV S 472 F
CHOV S 1157R
AGAGGGAGGCAGACTGTGA
CCCATAGACTGTGTCCTTCG
S 472 (sense)
S 1157 (antisense)
685 base pairs CHOV sequencing
Primers set 2
CHOV S 901 F
CHOV S 1480 R
GCTGAGTCTGAAGGTGCC
CCCTTAACCCTAAATTAGTGC
S 901 (sense)
S 1480 (antisense)
579 base pairs CHOV sequencing
Primers set 3
CHOV S 1260F
CHOV S 1972R
GCAGTTAGCACAGTCCTTAGTTG
TAGTAGTATGCTCCTTGAAAAGC
S 1260 (sense)
S 1972 (antisense)
712 base pairs CHOV sequencing
Primers set 4
CHOV S901 F
CHOV S1000R
CHOV S933P
GCTGAGTCTGAAGGTGCCAC
ATAGTGCTGTTGGTGGACA
FAM- CATTGCTGTCCCTCAC
TCTGTGTGG -BHQ1
S 901 (sense)
S1000 (antisense)
S933 (sense)
100 base pairs CHOV real-time
FAM: carboxyﬂuorescein (reporter); BHQ1: black hole quencher 1 (quencher).
a Position on CHOV genome based on DQ285046 (S segment) or EF397003 (L segment). All sequences shown in the 5′ to 3′ orientation.
b Previously published [3].
care unit for aggressive ﬂuid resuscitation, inotropes, and venti-
latory support for respiratory distress and severe capillary leak
syndrome.
Following discussions between on-call consultants and the UK
Imported Fever Service, samples were sent to Public Health Eng-
land (PHE), Porton Down, to test for potential dengue, hantavirus,
leptospirosis, Q-fever, and rickettsial infection.
Doxycycline, ceftriaxone, metronidazole, oseltamivir and high
dose co-trimoxazole were commenced immediately after admis-
sion; cessation of these regimens was implemented as the clinical
picture became increasingly compatible with HPCS and laboratory
tests ruled out speciﬁc differential diagnoses. Due to the sever-
ity of disease, ribavirin was commenced 48h after admission but
was stopped after subsequent agreement that there was lack of
supporting data for ribavirin therapy in New World hantavirus
infection.
The critical phase lasted 36h after which diuresis followed.
Ventilatory support was weaned over 14 days. The patient was
extubatedon1stAugust anddischargedon5thAugust aftermaking
an uneventful recovery.
Initial diagnosis of HCPS was made using anti-hantavirus IgG
indirect immunoﬂuorescence test mosaic 1 (Euroimmun). A serum
sample taken on 19th July (day 7 of illness) was positive for Sin
Nombre and Puumala IgG at dilutions of 1:100; two days later
serum titres had increased to 1:1000 for Sin Nombre IgG and 1:320
for Puumala IgG.
Molecular identiﬁcation of hantavirus RNA was made in the ini-
tial serum sample utilising a modiﬁed published pan-hantavirus
RT-PCR assay [3]. Sequence analysis of the second round PCR
product yielded an amplicon with 96% homology to the Choclo han-
tavirus (CHOV) L segment (Genbank accession number EF397003).
A set of PCR primers was designed to amplify the entire S segment
using the only published sequence available on Genbank (Table 1).
RT-PCR ampliﬁcation was performed using SuperScript III One-
Step RT-PCR System with Platinum Taq (Thermo Fisher Scientiﬁc).
The ﬁnal mastermix (25L) comprised 12.5L of 2×Reaction Mix
4.5L of PCR-grade water, 1L of both a forward and reverse
primer at 10M working concentration, 1L of SuperScript III
RT/Platinum Taq Mix and 5L of template. The cycling conditions
used were 50 ◦C for 15min, 95 ◦C for 2min, followed by 45 cycles
of 95 ◦C for 15 s, 52 ◦C for 30 s and 68 ◦C for 45 s, with a ﬁnal exten-
sion step of 68 ◦C for 5min. Bands of interest were excised from 2%
agarose gel and puriﬁed using QIAquick Gel Extraction Kit (Qiagen)
according to the manufacturer’s instructions.
Sequenceanalysis was performed using the same primers used
to produce the amplicons. Nucleotide labelling was carried out
using Big Dye® Terminator v3.1Cycle Sequencing Kit (Thermo
Fisher Scientiﬁc), unincorporated dye terminator was removed
using DyeEx 2.0 Spin Kit (Qiagen), and sequencing of products was
carried out on a 3130xl sequencer (Thermo Fisher Scientiﬁc) all
according to manufacturer’s instructions. Sequence data showed
homology to the soleCHOVpublishedonGenbank (98.6%across the
entire segment) and signiﬁcant divergence from other pathogenic
New World hantaviruses (Fig. 1).
Bootstrapped maximum likelihood analysis of complete han-
tavirus S segments showed a close relationship between the
sequenced virus and the sole CHOV sequence available onGenBank
(Fig. 2).
Attempts to isolate the virus from patient serum samples were
unsuccessful, presumably due to the low quantity of sample avail-
able for testing from the acute phase of illness and the apparent low
levels of viral RNApresent in the samples. A real-time RT-PCR assay
was designed to detect the CHOV S segment (Table 1) but ampliﬁ-
cation was only seen in the initial samples. All real-time RT-PCRs
were performed on the ABi 7500 (Thermo Fisher Scientiﬁc) using
the SuperScript III One-Step qRT-PCR System with Platinum Taq
(Thermo Fisher Scientiﬁc). The ﬁnal mastermix (20L) comprised
10L of 2×Reaction Mix 1.7L of PCR-grade water, 1L of both a
forwardandreverseprimerat18Mworkingconcentration, 0.5L
of probe at 25M working concentration, 0.8L of SuperScript III
RT/Platinum Taq Mix and 5L of template. The cycling conditions
used were 50 ◦C for 10min, 95 ◦C for 2min, followed by 45 cycles
of 95 ◦C for 10 s then 60 ◦C for 40 s (with quantiﬁcation analysis of
ﬂuorescence performed at the end of each 60 ◦C step).
3. Other similar and contrasting cases in the literature
HCPS is a severe disease caused by several viruses classiﬁed
within the Hantavirus genus of the family Bunyaviridae with a
case fatality rate of approximately 30–40% [4]. CHOV is the only
hantavirus associated with human disease known to circulate
in Panama; case fatality rates of approximately 25% have been
recorded [11] although seroprevalence studies indicate that a
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Fig. 1. Phylogenetic divergence/identity between full S segment data sequenced from the patient serum sample in relation to other pathogenic New World hantaviruses.
Data produced using MegAlign software v11 (Lasergene) following ClustalW alignment.
Fig. 2. Molecular phylogenetic analysis of full S segment hantavirus sequences bymaximum likelihoodmethod. The evolutionary historywas inferred by using themaximum
likelihood method based on the Tamura 3-parameter model conducted in MEGA6. The tree is drawn to scale, with branch lengths measured in the number of substitutions
per site. Analysis includes representative isolates for pathogenic ‘New World’ hantaviruses associated with hantavirus cardiopulmonary syndrome (HCPS) and ‘Old World’
hantaviruses associated with haemorrhagic fever with renal syndrome (HFRS). Branch labels include GenBank accession numbers; the sequence highlighted with a red box
designates the sequence in this report.
milder formofdiseasemayalsobepresent resulting inundiagnosed
cases [1].
Human exposure to hantaviruses occurs following inhalation of
aerosolised rodent excreta [5]. The reservoir for CHOV is the pygmy
rice rat (Oligoryzomys fulvescens costaricensis) [2]; this rodent is
known to thrive in agricultural environments, especially those
prone to anthropogenic change [10]. The patient in this report
lived near a rice farm in a known CHOV-endemic area of Panama
and reported activity in an environment with evidence of rodent
infestation.
The clinical course of disease was typical for HCPS and matched
wellwith the limiteddata available forhuman infectionwithCHOV.
The patient met all criteria for moderate to severe HCPS resulting
from infectionwith CHOV as previously documented, both in terms
of laboratory ﬁndings and symptoms of disease [1]. Creatinine lev-
els, which are often elevated following infection with both New
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World andOldWorld hantaviruses [7], were normal upon hospital-
ization but peaked at 127mol/L (norm: 50–95mol/L) two days
after admission. This increase in, combination with transient pro-
teinuria and microalbuminuria observed during the critical phase
of infection, indicate a degree of renal impairment.
4. Discussion
Clinical diagnosis of HCPS outside of the Americas is extremely
rare. To the best of our knowledge, this case represents only the
third report of HCPS imported into Europe following non-fatal
importations into France in 2001 [6] and Italy in 2010 [9] from
Chile and Cuba respectively; neither previous report had sequence
analysis to conﬁrm the causal hantavirus species.
Several cases of HCPS have been reported this year from the Los
Santos region of Panama where this patient resided before return-
ing to UK [8]. Reports emanating from Panama have not conﬁrmed
the species of hantavirus causing disease although, to date, CHOV
is the only pathogenic hantavirus known to circulate in the region.
The diagnostics used to conﬁrm this case show the robustness
of the initial molecular and serological assays to detect a rare strain
of hantavirus. In addition, the speciﬁc molecular assays developed
to determine the causative agent for this case report conﬁrmed that
CHOVRNAwas present in the patient sera. These diagnostics repre-
sent the ﬁrst published real-timeRT-PCR and sequencing strategies
for thediagnosis of this severehumanpathogenandmayproveuse-
ful for rapid species speciﬁc diagnostics in endemic areas and for
diagnosing cases in returning travellers worldwide.
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